Ocugen (NASDAQ:OCGN) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Ocugen (NASDAQ:OCGN) issued its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01), Zacks reports. Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%.

Here are the key takeaways from Ocugen’s conference call:

• Ocugen announced a $115 million convertible senior notes offering expected to close May 7, which management says would bring expected cash equivalents and restricted cash to $112.1 million (or $127.1 million if remaining warrants are exercised) and extend cash runway into 2028.
• Phase II data for OCU410 (GA) showed the medium dose produced a 31% reduction in lesion growth at 12 months versus control (p<0.05), ~2x the treatment effect of approved intravitreal therapies, with a favorable tolerability profile after a single one‑time subretinal injection.
• OCU400 (RP) completed enrollment in the 140‑patient LIMELIGHT Phase III trial, plans to begin a rolling BLA in Q3 2026, expects Phase III top‑line in Q1 2027 and potential approval targeted for Q4 2027, and cites durable 3‑year benefit and no drug‑related SAEs in earlier cohorts.
• OCU410ST (Stargardt) dosing in the pivotal GARDian3 trial finished ahead of schedule (63 patients); an interim outcome analysis is planned for Q3 2026 with top‑line data expected in Q2 2027 and a potential BLA mid‑2027, but the adaptive DMC review could require sample‑size adjustments and timing changes.
• Financials show rising spend and ongoing losses — Q1 operating expenses rose to $19.4 million with a $0.06 net loss per share and cash of $32.2 million as of March 31, 2026 (pre‑financing), meaning execution depends on the planned financing and future regulatory outcomes and may involve dilution or additional funding needs.

Ocugen Stock Performance

Shares of Ocugen stock traded down $0.37 during trading on Tuesday, hitting $1.49. 17,094,724 shares of the company’s stock traded hands, compared to its average volume of 7,519,063. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.06 and a quick ratio of 1.06. Ocugen has a 1 year low of $0.64 and a 1 year high of $2.73. The stock has a market capitalization of $502.70 million, a P/E ratio of -6.46 and a beta of 2.30. The business has a 50-day simple moving average of $1.88 and a 200-day simple moving average of $1.59.

Institutional Investors Weigh In On Ocugen

Institutional investors have recently modified their holdings of the business. Creative Planning purchased a new position in Ocugen in the second quarter worth about $57,000. XTX Topco Ltd purchased a new position in Ocugen in the second quarter worth about $203,000. Jump Financial LLC purchased a new position in Ocugen in the second quarter worth about $57,000. Qube Research & Technologies Ltd purchased a new position in Ocugen in the second quarter worth about $188,000. Finally, NewEdge Advisors LLC boosted its position in Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after purchasing an additional 24,460 shares during the last quarter. 10.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on OCGN shares. Canaccord Genuity Group started coverage on Ocugen in a report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price target for the company. Oppenheimer assumed coverage on Ocugen in a research report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Ocugen in a research report on Wednesday, March 25th. HC Wainwright increased their price objective on Ocugen from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Finally, Wall Street Zen cut Ocugen from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.75.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.